Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Aldeyra The

Healthcare US ALDX

1.755USD
-0.105(5.65%)

Last update at 2026-06-04T18:17:00Z

Day Range

1.751.93
LowHigh

52 Week Range

1.076.17
LowHigh

Fundamentals

  • Previous Close 1.86
  • Market Cap107.13M
  • Volume754109
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-35.01321M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.56

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -33.84666M -55.85144M -37.54251M -62.02464M -57.77627M
Minority interest - - - - -
Net income -33.84666M -55.85144M -37.54251M -61.36928M -59.25420M
Selling general administrative 9602351.00M 11.89M 13.34M 15.37M 11.28M
Selling and marketing expenses - - 0.26M - -
Gross profit -0.25199M -0.24962M -0.26278M - -
Reconciled depreciation 0.25M 0.25M 0.26M 0.26M 0.26M
Ebit -31.94135M -53.92520M -35.47107M -62.67999M -56.21954M
Ebitda -31.68936M -53.67558M -35.20829M -60.33054M -56.03417M
Depreciation and amortization 0.25M 0.25M 0.26M 2.35M 0.19M
Non operating income net other - - - 2.35M 0.19M
Operating income -35.26521M -60.11703M -42.79408M -62.67999M -56.21954M
Other operating expenses 35.27M 60.12M 42.79M 62.68M 56.22M
Interest expense 1.91M 1.93M 2.07M 1.69M 1.74M
Tax provision - - - - 0.00000M
Interest income 3.32M 6.19M 6.72M 2.35M 0.19M
Net interest income 1.42M 4.27M 4.70M 0.66M -1.55674M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -55851444.00000M - -0.65535M 1.48M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 35.01M 60.12M 42.79M 62.68M 56.22M
Cost of revenue 0.25M 0.25M 0.26M - -
Total other income expense net 1.42M 4.27M 5.25M 0.66M -1.55674M
Discontinued operations - - - - -
Net income from continuing ops -33.84666M -55.85144M -45.69171M -62.02464M -57.77627M
Net income applicable to common shares - - - -62.02464M -57.77627M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 72.06M 104.61M 148.33M 181.29M 233.14M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.74M 2.92M 0.52M 6.72M 2.96M
Total liab 27.81M 33.60M 28.53M 30.28M 27.40M
Total stockholder equity 44.25M 71.00M 119.80M 151.01M 205.74M
Deferred long term liab - - - - -
Other current liab 6.12M 12.12M -0.46354M 14.07M 10.52M
Common stock 0.06M 0.06M 0.06M 0.06M 0.06M
Capital stock 0.06M 0.06M 0.06M 0.06M 0.06M
Retained earnings -483.95725M -450.11059M -394.25915M -356.71664M -294.69200M
Other liab - - - - -
Good will - - - - -
Other assets - 2.21M 0.00000M - -
Cash 70.04M 54.53M 142.82M 144.42M 229.79M
Cash and equivalents - - - - -
Total current liabilities 27.81M 18.60M 22.26M 15.36M 11.77M
Current deferred revenue 6.00M 6.00M 6.00M - -
Net debt -54.51109M -39.22409M -127.16566M -128.33525M -213.93245M
Short term debt 15.53M 0.30M 15.39M 1.16M 0.23M
Short long term debt 15.25M 0.03M 15.15M 0.91M -
Short long term debt total 15.53M 15.30M 15.66M 16.08M 15.86M
Other stockholder equity 528.15M 521.02M 513.99M 507.77M 500.37M
Property plant equipment - - - 0.02M 0.03M
Total current assets 71.78M 104.07M 143.35M 181.02M 232.75M
Long term investments - - - - -
Net tangible assets - - - 151.01M 205.74M
Short term investments 0.00000M 46.62M 0.00000M 29.88M 0.00000M
Net receivables - - - 3.24M 125.00M
Long term debt - 15.00M - 14.92M 15.50M
Inventory - - - -3.24203M -
Accounts payable 0.16M 0.18M 1.34M 0.13M 1.02M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.04M 0.00000M -0.10394M -
Additional paid in capital - - - - -
Common stock total equity - - - 0.06M 0.06M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -356.71664M -294.69200M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.27M 4.46M 0.25M 0.35M
Deferred long term asset charges - - - - -
Non current assets total 0.28M 0.53M 4.98M 0.27M 0.38M
Capital lease obligations 0.28M 0.27M 0.51M 0.25M 0.35M
Long term debt total - - - 14.92M 15.50M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 47.74M -44.91575M 57.00M -29.93821M -0.00781M
Change to liabilities - - - 0.32M 5.20M
Total cashflows from investing activities 47736288.00M -44.91575M 30.00M -29.95453M -0.00781M
Net borrowings 0.00000M -0.29250M -1.04250M - -
Total cash from financing activities 1123556.00M -0.17142M -1.27022M 1.22M 194.50M
Change to operating activities - - - -2.55806M 6.80M
Net income -33846661.00000M -55.85144M -37.54251M -62.02464M -57.77627M
Change in cash 15514162.00M -88.29592M -1.59635M -85.37162M 151.93M
Begin period cash flow 54527092.00M 142.82M 144.42M 229.79M 77.86M
End period cash flow 70041254.00M 54.53M 142.82M 144.42M 229.79M
Total cash from operating activities -33345682.00000M -43.20875M -30.32613M -56.63719M -42.55591M
Issuance of capital stock - - - 0.00000M 189.81M
Depreciation -897557.00000M 0.25M 0.26M 0.26M 0.26M
Other cashflows from investing activities - -51999948.00000M - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - -0.53295M 1.22M 194.50M
Other cashflows from financing activities 1123554.88M 0.12M -0.53295M 0.10M 4.68M
Change to netincome - - - 8.29M 7.11M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.02M 0.00781M
Change receivables - - - - -
Cash flows other operating - - - -3.76045M 2.24M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -85.37162M 151.93M
Change in working capital -5.17800M 5.91M 0.86M -3.44414M 7.44M
Stock based compensation 6091413.00M 7.97M 5.75M 8.29M 7.11M
Other non cash items -4692871.82200M -1.49366M 0.34M 0.28M 0.41M
Free cash flow -33345682.00000M -43.20875M -30.32613M -56.65350M -42.56371M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ALDX
Aldeyra The		 -0.105 5.65% 1.75 - - - 2.43 6.96
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Aldeyra The

131 Hartwell Avenue, Lexington, MA, United States, 02421

Key Executives

Name Title Year Born
Dr. Todd C. Brady M.D., Ph.D. CEO, Pres & Director 1972
Dr. Stephen G. Machatha Ph.D. Chief Devel. Officer 1977
Mr. Bruce Greenberg CPA, M.B.A. VP of Fin., Interim CFO & Treasurer NA
Mr. Kelly Mizer VP of Commercial Strategy & Operations NA
Dr. Todd C. Brady M.D., Ph.D. CEO, President & Director 1972
Mr. Bruce Greenberg CPA, M.B.A. Senior VP of Finance, Interim CFO & Treasurer 1968
Dr. Stephen G. Machatha Ph.D. Chief Development Officer 1977
Mr. Kelly Mizer Vice President of Commercial Strategy & Operations NA
David Burke Head of Investor Relations NA
Mr. Michael Alfieri Principal Financial & Accounting Officer 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.